{
    "nct_id": "NCT06708754",
    "official_title": "PBM-LEF Study: The Impact of PBM on Biomarkers of Radiation Lymphedema and Fibrosis in Head and Neck Cancer Patients: A Feasibility Study",
    "inclusion_criteria": "* Patients treated with radiation for head and neck cancer who are ≥ 3 months < 36 months post-RT (last RT).\n* Patients who received at least 50Gy of bilateral neck RT. Subjects who received RT or concurrent chemoradiation (chemoRT) therapy for HNC are eligible.\n* No evidence of disease as documented by imaging 3 months after completion of RT.\n* Common Terminology Criteria for Adverse Events (CTCAE) fibrosis score ≥ 2 at enrollment.\n* Patient who has body mass index (BMI) >30 at the time of enrollment may be excluded at a discretion of the principal investigator if fibrotic areas cannot be identified by clinical objective assessment of fibrosis.\n* Willing to comply with all study procedures and be available for the duration of the study.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Woman who are pregnant or planning to become pregnant or breast-feeding.\n* Patients enrolled on another drug or device investigational trial for prevention or treatment of LEF.\n* Patients deprived of freedom, under supervision or guardianship.\n* Patients unable to attend to scheduled visits due to geographical, social or mental reasons.\n* Patients who received prior PBM therapy for RT toxicities in the last year;\n* Patients who report being photosensitive.\n* Patients who have chronic immunosuppression or are on current immunosuppressive therapies.\n* Any patient who, in the opinion of the investigator, is unable or unlikely to comply fully with the study requirements or procedures for any reason.",
    "miscellaneous_criteria": ""
}